Image

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jan 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Jan 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market, By Type (Medication, Surgery), Month (1-Month, 3-Month, 6-Month, Others), Route of Administration (Parenteral, Oral, Implants, Others), Gender (Girls, Boys), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

 

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market Analysis and Size

In the recent times, the central precocious puberty (CPP) treatment market is expected to grow rapidly during the forecast period 2023-2030. Gonadotropin-releasing hormone (GnRH) agonists may be widely used to treat CPP as they restrict the stimulating effects of endogenous GnRH and increase the bone development, avoiding early puberty. It has been witnessed that Triptodor, Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are the three approved therapy drugs for central precocious puberty currently on the market

Data Bridge Market Research analyses a growth rate in the central precocious puberty (CPP) treatment market in the forecast period 2023-2030. The expected CAGR of central precocious puberty (CPP) treatment market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 240 million in 2022, and it would grow up to USD 444.2 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Medication, Surgery), Month (1-Month, 3-Month, 6-Month, Others), Route of Administration (Parenteral, Oral, Implants, Others), Gender (Girls, Boys), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)

Market Players Covered

Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Ipsen Pharma (France), Arbor Pharmaceuticals (U.S.), Tolmar Pharmaceuticals, Inc. (U.S.), GP Pharm (Spain), Debiopharm (Switzerland), DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Endo International plc (Ireland), AstraZeneca (U.K.)

Market Opportunities

  • Increasing Prevalence of CPP in Girls
  • Rising Adoption of Direct Tender Segment

Market Definition

Central precocious puberty (CPP) treatment consists of features such as wide presence of novel pipeline drugs that will impact in launching several new products by the manufacturers into the central precocious puberty (CPP) treatment market that will increase its demand as well as high demand of disease specific treatment which leads the demand of accurate central precocious puberty (CPP) treatment. The mutations in the MKRN3 gene are the most commonly known genetic cause of central precocious puberty (CPP).   

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market Dynamics

Drivers

  • Increasing Product Launches and Collaborations

Several product launches and agreements are also started by the major companies’ globally which are also increasing the central precocious puberty (CPP) treatment market. For instance, AbbVie Inc. collaborated with Scripps Research in december 2019, which is a company that is focused on development of new therapeutic approaches to deal with the usual rare diseases. This collaboration aided the company to treat numerous kinds of diseases by improving its drug development procedure which will lead to earn more economic benefit. Furthermore, collaboration, business expansion, product launches, awards and several recognition, also joint ventures and other strategies by the market players is increasing the market growth in the central precocious puberty (CPP) treatment market which also aids in the benefit for organization to further improve their offering for central precocious puberty treatment.

Opportunities

  • Increasing Prevalence of CPP in Girls

It has been witnessed that girls segment is dominating in the central precocious puberty (CPP) treatment market as the prevalence of CPP is less common in boys compared to girls and it has the wide presence of high female ratio than the male population. One in every 5,000 to 10,000 girls is seen to be suffering from central precocious puberty. Though the occurrence of the illness is not so clear in boys, it is less widespread in boys. Thus, this boosts the market growth.   

  • Rising Adoption of Direct Tender Segment

The direct tender channel is hugely increasing the market growth as the drugs are used for the central precocious puberty (CPP) treatment which can be procured through direct tender on reasonable price and the patients receive treatment for extended period of time. Thus, this factor enhances the market growth.

Restraints/Challenges

  • High Cost of Treatment

There are several treatment methods that requires surgery and high-end medications that demand very heavy cost. The lower economic groups cannot access these treatment processes. Thus, this factor hampers the market growth as the treatment options are not feasible for all the economic groups.

  • Lack of Reimbursement Policies

There is a lack of reimbursement for central precocious puberty (CPP) treatment, which are projected to limit the market growth. Both public and private payers do not reimburse majority of the treatment services. The cost of such services varies hugely and there cannot be any standardization. Thus, this factor hampers the market growth.

This central precocious puberty (CPP) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the central precocious puberty (CPP) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Asia-Pacific Central Precocious Puberty (CPP) Treatment Market Scope

The central precocious puberty (CPP) treatment market is segmented on the basis of type, month, route of administration, gender, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Medication
  • Surgery

Month

  • 1-Month
  • 3-Month
  • 6-Month
  • Others

Route of Administration

  • Parenteral
  • Oral
  • Implants
  • Others

Gender

  • Girls
  • Boys

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Central Precocious Puberty (CPP) Treatment Market Regional Analysis/Insights

The central precocious puberty (CPP) treatment market is analyzed and market size insights and trends are provided by type, month, route of administration, gender, end user and distribution channel as referenced above.

The major countries covered in the central precocious puberty (CPP) treatment market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

Japan is expected to dominate in the market in the Asia-Pacific market because of the increase in occurrence of precocious puberty and increasing population of girls. 

China is one of the fastest growing countries due to rapidly changing lifestyle, and high usage of treatment options.   

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of asia-pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Asia-Pacific Central Precocious Puberty (CPP) Treatment Market  Share Analysis

The central precocious puberty (CPP) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, asia-pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to central precocious puberty (CPP) treatment market.

Key players operating in the central precocious puberty (CPP) treatment market include:

  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Ipsen Pharma (France)
  • Arbor Pharmaceuticals (U.S.)
  • Tolmar Pharmaceuticals, Inc. (U.S.)
  • GP Pharm (Spain)
  • Debiopharm (Switzerland)
  • DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Endo International plc (Ireland)
  • AstraZeneca (U.K.)


SKU-
Why Choose Us


Frequently Asked Questions

The Asia-Pacific Central Precocious Puberty (CPP) Treatment Market is projected to grow at a CAGR of 8.0% during the forecast period by 2030.
The future market value of the Asia-Pacific Central Precocious Puberty (CPP) Treatment Market is expected to reach USD 444.2 million by 2030.
The major players in the Asia-Pacific Central Precocious Puberty (CPP) Treatment Market are Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), etc.
The countries covered in the Asia-Pacific Central Precocious Puberty (CPP) Treatment Market are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).